Navigation Links
Huntsman Cancer Institute Uses Linguamatics I2E to Automatically Extract Insights from Clinical Pathology Documents
Date:11/18/2013

CAMBRIDGE, England and BOSTON, Nov. 18, 2013 /PRNewswire/ -- Linguamatics, the leader in natural language processing-based text mining and analytics, today announced that Huntsman Cancer Institute (HCI) at the University of Utah has deployed its natural language processing (NLP) based I2E software platform to transform the immense stores of unstructured text in electronic health records (EHRs) into actionable information to drive improvements in cancer research, treatments and outcomes.

HCI is using Linguamatics I2E with its in-house clinical informatics infrastructure to extract discrete data from the unstructured text contained in surgical, pathology, radiology, and clinical notes related to hematology oncology disease areas such as Leukemia and Lymphoma. The resulting data is loaded into an integrated biobanking, clinical research, and genomic annotation platform. This enables HCI's clinicians and principal investigators to harness the richest possible set of data for research into patient outcomes, comparative effectiveness, and genetic drivers of disease. Analysis at this scale can find information that would often be missed when reading documents one at a time. In addition HCI has a better range and quality of data to support clinical trial matching and increase numbers of patients on trials.

"Healthcare organizations face a major challenge to identify, capture and leverage valuable knowledge buried within vast stores of complex, unstructured patient data, and to do it in a reproducible and scalable way," commented Phil Hastings, Snr Vice President, Sales and Marketing, at Linguamatics. "When abstracting detailed patient data, a clinical research assistant may look at multiple documents and spend several hours per patient to get all their radiology, pathology and surgical data curated. To perform this work at a meaningful scale is both laborious and expensive."

"I2E is a uniquely agile and scalable NLP platform, which empowers organizations to successfully address the data abstraction challenge," continued Dr Hastings. "We are pleased to be working with Huntsman Cancer Institute in their drive to streamline and extend their healthcare analytics efforts and positively impact research processes and patient outcomes."

ABOUT LINGUAMATICS
Linguamatics is the world leader in innovative health science focused natural language processing (NLP) solutions for high-value knowledge discovery, information extraction and decision support.

Linguamatics I2E text mining platform is used by leading hospitals, the U.S. Food and Drug Administration, premier academic institutions and nine of the top ten pharmaceuticals to transform unstructured and semi structured data into improved patient care and insights. I2E is able to mine any text-based resources, such as electronic health records, pathology and radiology reports, initial assessments, discharge summaries and ICU notes to support knowledge extraction for use in data warehouses, biobanks, disease registries, predictive models and healthcare analytics. I2E allows medical information experts who are not developers to quickly build and modify queries that extract information which is critical to supporting Meaningful Use, comparative effectiveness and adherence to care pathways.

Linguamatics is committed to excellence in healthcare informatics and is a corporate member of AMIA, HIMSS and the MLA. The company operates globally, with headquarters in Cambridge, UK, and a U.S. office near Boston, MA. For more information, visit www.linguamatics.com/healthcare or www.whatistextmining.com.

Contact:

Danielle Guinebertiere
Office: +1 978 254 5587
Email

Read more news from Linguamatics.

 


'/>"/>
SOURCE Linguamatics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
3. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
4. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
5. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
6. Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS
7. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
8. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
9. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
10. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
11. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)...  On January 10 at the Medtech Showcase held ... Conference in San Francisco , ProclaRx ... to pharmaceutical leaders and public and private investors about ... and destroy biofilms.  Biofilms are a ... the body,s immune system from eradicating chronic infections. Infections with ...
(Date:1/16/2017)... Jan. 16, 2017  Eurofins Genomics today announced the ... more customers to receive their primers in a shorter ... in quality found with other providers. Express oligos are ... at no additional fee. Researchers ... studies, including DNA sequencing, genotyping, site-directed mutagenesis, and cloning. ...
(Date:1/13/2017)... Research and Markets has announced the addition of the "Global ... ... CAGR of 16.83% during the period 2017-2021. The report ... market for 2017-2021. To calculate the market size, the report considers the ... also includes a a discussion of the key vendors operating in this ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... SUCCESS , VTI, Vertebral Technologies, Inc., announces the successful outcome of the ... Since September 2016, VTI (Vertebral Technologies, Inc.) has partnered with Mexico-based medical ...
Breaking Biology Technology:
(Date:12/7/2016)... Dec. 7, 2016   Veridium , a ... appointment of new CEO James Stickland . ... decades of experience, has served in senior executive ... he specialized in expanding a pipeline of venture ... He most recently served as managing director of ...
(Date:12/6/2016)... Valencell , the leading innovator in performance biometric ... consecutive year of triple digit growth for its PerformTek ... 360 percent increase in companies who have acquired Valencell ... sales of its wrist and ear Benchmark™ sensor systems, ... hearables for fitness and healthcare applications. ...
(Date:12/5/2016)... 2016  The Office of Justice Programs, National ... Scans Enhance or Replace Medico Legal Autopsies?" on ... or replacing forensic autopsies with postmortem X-ray computed ... In response to recommendations made by The National ... scans as a potential component of medicolegal death ...
Breaking Biology News(10 mins):